Web Exclusives
- Statistical Advantage
-
Gary Shorter, director of biostatistics for Quintiles, talks to Envisage editor Adam Istas about the growing importance of incorporating biostatistical analysis into all stages of drug development.
- Measure for Measure
-
A proposed Health Care Comparative Effectiveness Research Institute in the United States may force the biopharmaceutical industry to emphasize patient outcomes and quality of life issues when developing a new medicinal product.
- Evidence-Based Development and Smarter Sourcing
-
Jay Norman, president of Quintiles Consulting, discusses the changing landscape of drug development and suggests that better, evidence-based decisions, combined with smart sourcing strategies, will differentiate the future winners.
- An Unbalanced Burden
-
A Q&A with Dr. Kathleen Squires, director of the infectious disease department at Jefferson Medical College in Philadelphia, illuminates the gender differences in the diagnosis and treatment of HIV.
- Turning the Corner
-
After decades of neglect, leading to a rapid increase in incidence, tuberculosis started gaining attention from industrialized nations over the past 10 years. With this new focus, TB’s incidence has started to decrease—but barely.
- A Weighty Problem
-
As pharmaceutical companies search for a blockbuster fat-fighting drug, the biggest battle is against side effects.
- Ahead of the Curve
-
As a follow-on biologics pathway inches closer to reality, interested companies must consider biologics’ unique characteristics when preparing to enter the game.
- Unanswered Questions
-
As the number of asthma cases climb globally, researchers focus on early intervention and effective treatments.
- A United Front
-
New partnerships aid the global fight against malaria.
- Changes Ahead
-
The Food and Drug Administration Amendments Act of 2007 increases FDA funding, raising questions about the future of how the agency regulates drug marketing.
- Small Steps Forward
-
Despite some significant setbacks, the search for an AIDS vaccine continues in earnest.
- In Science We Trust
-
Genentech’s unique model for biopharmaceutical development partnering stresses that science and flexibility are the keys to success.
- The New Flavor of PDUFA
-
While enhancing post-marketing safety surveillance of pharmaceutical products is a legislative concern in the United States, many wonder whether the various drug safety initiatives go far enough.
- One World, One Name
-
The goals of fostering public understanding and safety compel pharmaceutical companies to take care when naming nonproprietary drugs.
- Transfer Tactic
-
A novel technology platform may hold the potential to significantly advance the treatment of neurodegenerative disorders.
- Alternative Delivery
-
Developing novel mechanisms for drug delivery requires creativity and sound scientific platforms, but changing patient and physician behavior is often a greater challenge.
- On the Mark
-
In an effort to modernize drug development, the Predictive Safety Testing Consortium enables companies to share and validate safety biomarkers.
- Vaccine Acceleration
-
Innovative trial design, effective partnerships and advances in biotechnology continue to move vaccine development into the 21st century.
- Reaching Out
-
In order to recruit a more ethnically diverse pool of patients, investigators and clinical trial coordinators are seeking buy-in from community leaders.
- On the Doorstep
-
As personalized medicine advances, the drug development community is making adjustments.
- Transparency and Trust
-
With the issue of clinical trial registration settled, the movement to disclose all trial results is taking center stage.
Web Exclusives
- Statistical Advantage
-
Gary Shorter, director of biostatistics for Quintiles, talks to Envisage editor Adam Istas about the growing importance of incorporating biostatistical analysis into all stages of drug development.
- Measure for Measure
-
A proposed Health Care Comparative Effectiveness Research Institute in the United States may force the biopharmaceutical industry to emphasize patient outcomes and quality of life issues when developing a new medicinal product.